phase readout
saveNCT04788615: Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS
COMPLETEDupdated 8m ago
community read0 votes
Sponsor: Novartis Pharmaceuticals. Phase: PHASE3. Conditions: Multiple Sclerosis
view source ↗
comments(0)
5-min edit window · permanent after that